Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Journal of Urology

Volumn 170, Issue 2 I, 2003, Pages 498-502

  Narayan, Perinchery ^a   Evans, Christopher P ^a   Moon, Timothy ^a  

^a NONE

Author keywords

Adrenergic alpha antagonists; Prostate; Prostatic hyperplasia; Urination disorders

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EJACULATION DISORDER; FLU LIKE SYNDROME; HEART INFARCTION; HUMAN; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RHINITIS; SINUSITIS; SKIN CANCER; SYNCOPE; THORAX PAIN; VERTIGO;

EID: 0038507245     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000076140.68657.fd     Document Type: Article

References (14)

1. Berry, S. J., Coffey, D. S., Walsh, P. C. and Ewing, L. L.: The development of human benign prostatic hyperplasia with age. J Urol, 132: 474, 1984
2. Narayan, P., Tewari, A. and Members of the United States 93-01 Study Group: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol, 160: 1701, 1998
3. Lepor, H.: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology, 51: 892, 1998
4. Lepor, H.: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology, 51: 901, 1998
5. Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A. F. and Abrams, P.: Tamsulosin, the first prostate-selective alpha1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol, 29: 155, 1996
6. Lowe, F. C.: Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther, 19: 730, 1997
7. Narayan, P. and Lepor, H.: Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57: 466, 2001
8. Barry, M. J., Fowler, F. J., Jr., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L. and Mebust, W. K.: Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care, suppl., 33: AS145, 1995
9. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 338: 557, 1998
10. Lepor, H., Kaplan, S. A., Klimberg, I., Mobley, D. F., Fawzy, A., Gaffney, M. et al: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol, 157: 525, 1997
11. Lepor, H.: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology, 45: 406, 1995
12. Hofner, K., Claes, H., De Reijke, T. M., Folkestad, B. and Speakman, M. J.: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol, 36: 335, 1999
13. Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D. et al: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Pless Study Group. Proscar Long-Term Efficacy and Safety Study. Urology, 52: 195, 1998
14. Evans, C., Doyle, C. A. and Ranhosky, A.: PSA levels and occurrence of prostate cancer during long-term study (6 years) of treatment with tamsulosin for BPH. J Urol, suppl., 165: 382, abstract 1564, 2001